{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:38:15Z","timestamp":1792298295641,"version":"4.4.0"},"reference-count":100,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T00:00:00Z","timestamp":1389225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Bone is the most common site of metastasis from breast cancer. Bone metastases from breast cancer are associated with skeletal-related events (SREs) including pathological fractures, spinal cord compression, surgery and radiotherapy to bone, as well as bone pain and hypercalcemia, leading to impaired mobility and reduced quality of life. Greater understanding of the pathophysiology of bone metastases has led to the discovery and clinical utility of bone-targeted agents such as bisphosphonates and the receptor activator of nuclear factor kappa-B ligand (RANK-L) antibody, denosumab. Both are now a routine part of the treatment of breast cancer bone metastases to reduce SREs. With regards to prevention, there is no evidence that oral bisphosphonates can prevent bone metastases in advanced breast cancer without skeletal involvement. Several phase III clinical trials have evaluated bisphosphonates as adjuvant therapy in early breast cancer to prevent bone metastases. The current published data do not support the routine use of bisphosphonates in unselected patients with early breast cancer for metastasis prevention. However, significant benefit of adjuvant bisphosphonates has been consistently observed in the postmenopausal or ovarian suppression subgroup across multiple clinical trials, which raises the hypothesis that its greatest anti-tumor effect is in a low estrogen microenvironment. An individual patient data meta-analysis will be required to confirm survival benefit in this setting. This review summarizes the key evidence for current clinical practice and future directions.<\/jats:p>","DOI":"10.3390\/jcm3010001","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T14:10:57Z","timestamp":1389276657000},"page":"1-24","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Treatment and Prevention of Bone Metastases from  Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice"],"prefix":"10.3390","volume":"3","author":[{"given":"Bob","family":"Li","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Royal North Shore Hospital, St. Leonards NSW 2065, Sydney, Australia"},{"name":"Sydney Medical School, University of Sydney, Camperdown NSW 2050, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wong","sequence":"additional","affiliation":[{"name":"Sydney Medical School, University of Sydney, Camperdown NSW 2050, Sydney, Australia"},{"name":"Department of Medical Oncology, Gosford Hospital, Gosford NSW 2250, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Royal North Shore Hospital, St. Leonards NSW 2065, Sydney, Australia"},{"name":"Sydney Medical School, University of Sydney, Camperdown NSW 2050, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2014,1,9]]},"reference":[{"key":"ref_1","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA: Cancer J. Clin."},{"key":"ref_2","first-page":"74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA: Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.ejca.2009.04.022","article-title":"Adjuvant bisphosphonates in breast cancer: Are we witnessing the emergence of a new therapeutic strategy?","volume":"45","author":"Coleman","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.2000.18.23.3925","article-title":"Identifying breast cancer patients at high risk for bone metastases","volume":"18","author":"Colleoni","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.humpath.2008.05.010","article-title":"Bone metastasis is strongly associated with estrogen receptor-positive\/progesterone receptor-negative breast carcinomas","volume":"39","author":"Wei","year":"2008","journal-title":"Hum. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1200\/JCO.2007.14.1168","article-title":"Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer","volume":"26","author":"Dawood","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"Br. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/cncr.20545","article-title":"Metastatic breast carcinoma confined to bone: Portrait of a clinical entity","volume":"101","author":"Briasoulis","year":"2004","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/1097-0142(20000715)89:2<363::AID-CNCR22>3.0.CO;2-3","article-title":"Predictors of skeletal complications in patients with metastatic breast carcinoma","volume":"89","author":"Domchek","year":"2000","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrc865","article-title":"Dissemination and growth of cancer cells in metastatic sites","volume":"2","author":"Chambers","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1535-6108(03)00132-6","article-title":"A multigenic program mediating breast cancer metastasis to bone","volume":"3","author":"Kang","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","article-title":"The distribution of secondary growths in cancer of the breast","volume":"133","author":"Paget","year":"1889","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrc2621","article-title":"The metastatic niche: Adapting the foreign soil","volume":"9","author":"Psaila","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1646::AID-CNCR14>3.0.CO;2-#","article-title":"Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma","volume":"80","author":"Harvey","year":"1997","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/BCTT.S6655","article-title":"Optimal management of bone metastases in breast cancer patients","volume":"3","author":"Wong","year":"2011","journal-title":"Breast Cancer Targets Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminoncol.2010.10.007","article-title":"Examining the metastatic niche: Targeting the microenvironment","volume":"37","author":"Guise","year":"2010","journal-title":"Semin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1158\/1078-0432.CCR-06-1007","article-title":"Basic mechanisms responsible for osteolytic and osteoblastic bone metastases","volume":"12","author":"Guise","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Clines, G.A., and Guise, T.A. (2008). Molecular mechanisms and treatment of bone metastasis. Expert Rev. Mol. Med., 10.","DOI":"10.1017\/S1462399408000616"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6258","DOI":"10.1158\/1078-0432.CCR-06-0840","article-title":"Breast cancer: Bisphosphonate therapy for metastatic bone disease","volume":"12","author":"Body","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Clinical practice. Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6222","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: Current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wong, M.H., Stockler, M.R., and Pavlakis, N. (2012). Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst. Rev., 2.","DOI":"10.1002\/14651858.CD003474.pub3"},{"key":"ref_26","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Barrett-Lee, P.J., Casbard, A., Abraham, J., Grieve, R., Wheatley, D., Simmons, P., Coleman, R., Hood, K., Griffiths, G., and Murray, N. (2012). Zoledronate versus ibandronate comparative evaluation (ZICE) trial\u2014First results of a UK NCRI 1405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Res., 72.","DOI":"10.1158\/0008-5472.SABCS12-PD07-09"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1200\/jco.2004.22.90140.857","article-title":"Zoledronic acid versus pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications","volume":"22","author":"Kaminski","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Temin","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_31","unstructured":"National Breast and Ovarian Cancer Centre (2011). Recommendations for Use of Bisphosphonates for Advanced Breast Cancer, Cancer Australia."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): A phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1834-7819.2010.01283.x","article-title":"A review of the clinical implications of bisphosphonates in dentistry","volume":"56","author":"Borromeo","year":"2011","journal-title":"Aust. Dent. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-010-0135-y","article-title":"Denosumab in breast cancer","volume":"13","author":"Lipton","year":"2011","journal-title":"Curr. Oncol. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1200\/jco.2010.28.15_suppl.1024","article-title":"Effects of denosumab versus zoledronic acid on pain in patients with metastatic breast cancer: Results from a phase III clinical trial","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: Clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.1158\/1078-0432.CCR-06-0682","article-title":"Biology of bone cancer pain","volume":"12","author":"Goblirsch","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wong, R., and Wiffen, P.J. (2002). Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst. Rev., 2.","DOI":"10.1002\/14651858.CD002068"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00520-007-0244-9","article-title":"Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: A review","volume":"15","author":"Diel","year":"2007","journal-title":"Support Care Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1200\/JCO.2006.05.9212","article-title":"Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy","volume":"24","author":"Clemons","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","article-title":"Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer","volume":"40","author":"Diel","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0305-7372(03)00013-6","article-title":"Bisphosphonates and radiation therapy for palliation of metastatic bone disease","volume":"29","author":"Hoskin","year":"2003","journal-title":"Cancer Treat. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1200\/JCO.2006.09.5281","article-title":"Palliative radiotherapy trials for bone metastases: A systematic review","volume":"25","author":"Chow","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.radonc.2012.12.009","article-title":"Single fraction conventional external beam radiation therapy for bone metastases: A systematic review of randomised controlled trials","volume":"106","author":"Dennis","year":"2013","journal-title":"Radiother. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"9502","DOI":"10.1200\/jco.2013.31.15_suppl.9502","article-title":"A randomized trial of single versus multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20","volume":"31","author":"Chow","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2010.11.026","article-title":"Palliative radiotherapy for bone metastases: An ASTRO evidence-based guideline","volume":"79","author":"Lutz","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MNM.0b013e32805b72a0","article-title":"89Sr versus 153Sm-EDTMP: Comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma","volume":"28","author":"Baczyk","year":"2007","journal-title":"Nucl. Med. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0959-8049(99)00331-7","article-title":"Risk of complications from bone metastases in breast cancer: Implications for management","volume":"36","author":"Plunkett","year":"2000","journal-title":"Eur. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0140-6736(05)66954-1","article-title":"Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: A randomised trial","volume":"366","author":"Patchell","year":"2005","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1022166517963","article-title":"Estrogen receptors and distinct patterns of breast cancer relapse","volume":"78","author":"Hess","year":"2003","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/0008-5472.CAN-07-5644","article-title":"Subtypes of breast cancer show preferential site of relapse","volume":"68","author":"Smid","year":"2008","journal-title":"Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdp261","article-title":"Third consensus on medical treatment of metastatic breast cancer","volume":"20","author":"Beslija","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/onc.2009.426","article-title":"Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis","volume":"29","author":"Petersen","year":"2010","journal-title":"Oncogene"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10549-008-0184-1","article-title":"Transforming growth factor-beta signaling: Emerging stem cell target in metastatic breast cancer?","volume":"115","author":"Tan","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_62","unstructured":"National Institutes of Health A service of the US National Institutes of Health, Available online:http:\/\/clinicaltrials.gov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccr.2009.05.017","article-title":"Latent bone metastasis in breast cancer tied to Src-dependent survival signals","volume":"16","author":"Zhang","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.ejca.2010.04.012","article-title":"Combining Src inhibitors and aromatase inhibitors: A novel strategy for overcoming endocrine resistance and bone loss","volume":"46","author":"Hiscox","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/sj.bjc.6603959","article-title":"Increased Dickkopf-1 expression in breast cancer bone metastases","volume":"97","author":"Goehrig","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0959-8049(95)00564-1","article-title":"Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?","volume":"32","author":"Hermans","year":"1996","journal-title":"Eur. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm0806-875","article-title":"Is cancer a disease of self-seeding?","volume":"12","author":"Norton","year":"2006","journal-title":"Nat. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","article-title":"Tumor self-seeding by circulating cancer cells","volume":"139","author":"Kim","year":"2009","journal-title":"Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1078-0432.CCR-07-2223","article-title":"The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance","volume":"14","author":"Meads","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMoa050434","article-title":"A pooled analysis of bone marrow micrometastasis in breast cancer","volume":"353","author":"Braun","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","article-title":"Exploring the anti-tumour activity of bisphosphonates in early breast cancer","volume":"34","author":"Winter","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0093-7754(01)90263-5","article-title":"Preclinical studies with zoledronic acid and other bisphosphonates: Impact on the bone microenvironment","volume":"28","author":"Mundy","year":"2001","journal-title":"Semin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00262-008-0521-6","article-title":"In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients","volume":"58","author":"Santini","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/ijc.20602","article-title":"Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells","volume":"113","author":"Evans","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_76","first-page":"1807","article-title":"Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer","volume":"30","author":"Rack","year":"2010","journal-title":"Anticancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: An open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1200\/jco.2010.28.15_suppl.1002","article-title":"Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results","volume":"28","author":"Greenberg","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: A long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Powles, T., Paterson, A., McCloskey, E., Schein, P., Scheffler, B., Tidy, A., Ashley, S., Smith, I., Ottestad, L., and Kanis, J. (2006). Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res., 8.","DOI":"10.1186\/bcr1384"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-Year results of a randomized controlled trial","volume":"19","author":"Saarto","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/sj.bjc.6603661","article-title":"Meta-analysis of clodronate and breast cancer survival","volume":"96","author":"Ha","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): A multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Von Minckwitz, G., Mobus, V., Schneeweiss, A., Huober, J., Thomssen, C., Untch, M., Jackisch, C., Diel, I.J., Elling, D., and Conrad, B. (2013). German adjuvant intergroup node-positive study: A phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. Am. Soc. Clin. Oncol., 31.","DOI":"10.1200\/JCO.2012.47.2167"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-Month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11912-011-0209-5","article-title":"Zoledronic acid in the treatment of early-stage breast cancer: Is there a final verdict?","volume":"14","author":"Gnant","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/1758834011420599","article-title":"Zoledronic acid in breast cancer: Latest findings and interpretations","volume":"3","author":"Gnant","year":"2011","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","article-title":"Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-Month analysis of the E-ZO-FAST trial","volume":"12","author":"Llombart","year":"2012","journal-title":"Clin. Breast Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejca.2011.10.021","article-title":"The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials","volume":"48","author":"Yan","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.2012-0261","article-title":"Adjuvant therapy with zoledronic acid in patients with breast cancer: A systematic review and meta-analysis","volume":"18","author":"Valachis","year":"2013","journal-title":"Oncologist"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1158\/1078-0432.CCR-06-1070","article-title":"Genomics and proteomics of bone cancer","volume":"12","author":"Marguiles","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nrd3181","article-title":"Personalized medicine in oncology: The future is now","volume":"9","author":"Schilsky","year":"2010","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/3\/1\/1\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:07:13Z","timestamp":1760216833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/3\/1\/1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,9]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,3]]}},"alternative-id":["jcm3010001"],"URL":"https:\/\/doi.org\/10.3390\/jcm3010001","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,9]]}}}